Hugan tablet sales temporarily halted

The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.

The product contributes ~$600K in annual sales.

The company expects the examination to be over in April and sales will recommence.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs